Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). In a filing disclosed on February 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ligand Pharmaceuticals stock on January 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Banco Santander (NYSE:SAN) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Leonardo (OTCMKTS:FINMF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of Cloudflare (NYSE:NET) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 1/30/2026.

Ligand Pharmaceuticals Price Performance

Shares of NASDAQ:LGND traded down $2.34 during trading on Friday, reaching $183.98. 163,846 shares of the company traded hands, compared to its average volume of 176,651. The firm has a market capitalization of $3.62 billion, a PE ratio of 88.88 and a beta of 1.14. Ligand Pharmaceuticals Incorporated has a 52 week low of $93.58 and a 52 week high of $212.49. The company has a quick ratio of 24.30, a current ratio of 24.69 and a debt-to-equity ratio of 0.47. The company’s 50 day moving average is $193.87 and its two-hundred day moving average is $183.71.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LGND. Salomon & Ludwin LLC acquired a new stake in shares of Ligand Pharmaceuticals during the third quarter worth $26,000. CIBC Private Wealth Group LLC raised its position in shares of Ligand Pharmaceuticals by 86.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 69 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Ligand Pharmaceuticals in the 4th quarter worth about $31,000. Richardson Financial Services Inc. boosted its position in shares of Ligand Pharmaceuticals by 85.8% during the 3rd quarter. Richardson Financial Services Inc. now owns 210 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 97 shares in the last quarter. Finally, USA Financial Formulas acquired a new position in Ligand Pharmaceuticals in the fourth quarter valued at approximately $43,000. Institutional investors own 91.28% of the company’s stock.

Insider Buying and Selling

In related news, CFO Octavio Espinoza sold 1,804 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $188.31, for a total transaction of $339,711.24. Following the transaction, the chief financial officer directly owned 26,186 shares of the company’s stock, valued at approximately $4,931,085.66. This represents a 6.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $195.91, for a total value of $91,489.97. Following the transaction, the director directly owned 43,187 shares in the company, valued at approximately $8,460,765.17. The trade was a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,205 shares of company stock worth $611,192 over the last 90 days. Company insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LGND. HC Wainwright increased their price objective on shares of Ligand Pharmaceuticals from $206.00 to $231.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, November 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Ligand Pharmaceuticals in a research report on Monday, December 29th. Stifel Nicolaus increased their target price on Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada lifted their price target on Ligand Pharmaceuticals from $234.00 to $235.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $239.33.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.